Potent Tetracyclic Guanine Inhibitors of PDE1 and PDE5 Cyclic Guanosine Monophosphate Phosphodiesterases with Oral Antihypertensive Activity

Abstract

Tetracyclic guanines have been shown to be potent and selective inhibitors of the cGMP-hydrolyzing enzymes PDE1 and PDE5. In general, these compounds are inactive or only weakly active as inhibitors of PDE3, which is a major isozyme involved in cAMP hydrolysis. Structure-activity relationships are developed at N-1, C-2, N-3, and N-5 on the core nucleus. Compound 31, with an IC50 of 70 pM, is the most potent inhibitor of PDE1, while 50, with an IC50 of 4 nM, is the most potent inhibitor of PDE5. Compounds 20, 22, 30, and 50 are potent dual inhibitors with IC50 values below 30 nM for both PDE1 and PDE5. Compounds 12, 20, and 28 reduced blood pressure by more than 45 mmHg when administered orally at 10 mg/kg to the spontaneously hypertensive rat (SHR).

Investigational phosphodiesterase inhibitors in phase I and phase II clinical trials for Alzheimer’s disease

“…First PDE1 inhibitors developed including IBMX [51] were not very specific for PDE1. For instance IBMX also inhibits PDE5 [15].…”

Phosphodiesterase 5 (PDE 5) inhibitors for the treatment of male erectile disorder: Attaining selectivity versus PDE6

“…The cyclic guanine scaffold of type 100 was initially targeted at Schering-Plough as a template for the discovery of antihypertensive drugs 98,99 acting as dual inhibitors of both PDE5 and PDE1 (Fig. 19).…”

Synthesis and Antiplatelet Activity of New Imidazole‐4‐Carboxylic Acid Derivatives

“…The synthesis of the desired imidazole compounds was carried out according to the elegant 3 ϩ 1 ϩ 1 method of Ahn et al [4]; it is summarized in Figure 1. Starting from nitrosoaceticacid-ester 1, which contributes the positions 3, 4, and 5 of the imidazole ring system, the aminoaceticacidester 2 is obtained through reduction with sodium dithionite.…”